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Abstract
The European Commission requested EFSA to carry out a scientiﬁc evaluation on four studies on the
potential toxicity of titanium dioxide (TiO2) used as a food additive (E 171) and to indicate whether
they would merit re-opening the existing opinion of EFSA on the safety of TiO2 (E 171) as a food
additive. The results of the Bettini et al. (2017) study did not provide enough justiﬁcation for a new
carcinogenicity study, but, should additional useful mechanistic information become available, this
could be reconsidered in future. The new in vitro ﬁndings in the Proquin et al. (2017) study did not
modify the conclusion on the genotoxicity of TiO2 as stated in the previous EFSA opinion of 2016 on
the safety of TiO2 (E 171) as a food additive. The effects of engineered TiO2 nanoparticles reported by
the Guo et al. (2017) study were of uncertain biological signiﬁcance and therefore of limited relevance
for the risk assessment of the food additive TiO2 (E 171). There was signiﬁcant uncertainty in the risk
assessment performed by Heringa et al. (2016), which did not include a weight of evidence analysis of
the whole database. The Panel considered that the four studies evaluated, highlighted some concerns
but with uncertainties, therefore their relevance for the risk assessment was considered limited and
further research would be needed to decrease the level of uncertainties. Overall, three of the studies,
reporting that TiO2 induced various effects in in vitro and in vivo models, may be useful for hazard
identiﬁcation of TiO2. In the fourth study by Heringa et al. (2016), numerous assumptions were made,
which resulted in large uncertainty in their conclusion. Altogether, the Panel concluded that the
outcome of the four studies did not merit re-opening the existing opinion of EFSA related to the safety
of TiO2 (E 171) as a food additive.
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Summary
The re-evaluation of titanium dioxide (TiO2, E 171) for use as a food additive had been completed
by the European Food Safety Authority (EFSA) Panel on Food Additives and Nutrient sources added to
food (ANS) in June 2016, and a scientiﬁc opinion published in September 2016 (EFSA ANS Panel,
2016). In 2017, the European Commission (EC) launched a call for data on TiO2 (E 171) inviting
interested business operators to generate the additional data requested. In particular, data on particle
size and particle size distribution for TiO2 (E 171) would be submitted by June 2018, whereas a dietary
Extended One-Generation Reproductive Toxicity Study with TiO2 (E 171) would be generated by
August 2019.
On 22 March 2018, the EC, in accordance with Article 29(1)(a) of Regulation (EC) No 178/2002,
requested EFSA to provide a scientiﬁc opinion in relation to four new studies (Heringa et al., 2016;
Bettini et al., 2017; Guo et al., 2017; Proquin et al., 2017), published after the scientiﬁc opinion in
2016, on the potential toxicity of TiO2 used as a food additive (E 171). In particular, EFSA is requested
to carry out a scientiﬁc evaluation of those studies and to indicate whether they would merit re-
opening the existing opinion of EFSA related to the safety of TiO2 (E 171) as a food additive.
The authors of these four publications were also invited to join the ANS plenary meeting open to
observers on 16 May 2018 as hearing experts, in order to present an overview on their studies and to
answer questions and to comment on their ﬁndings. The main points and outcome of that discussion
have been considered in developing this document.
The Panel was aware of other publications that have been published after the publication of the
scientiﬁc opinion on the re-evaluation of TiO2 (E 171) as a food additive in 2016 (EFSA ANS Panel), but
these were not taken into consideration in this evaluation, which is restricted to the four publications
included in the EC request. Individual publications should be assessed in respect to the whole data set
available, using a weight of evidence approach (EFSA Scientiﬁc Committee, 2017b). A proper evaluation
of the safety of TiO2 as a food additive would require considering all data available and not only selected
data. The EFSA SC also provided Guidance on when the database should be re-evaluated in light of new
evidence (EFSA Scientiﬁc Committee, 2017a).
The Panel has assessed the four publications as requested in the last mandate from the EC and
made speciﬁc comments on each individual studies which have been considered in the context of the
conclusions of the EFSA opinion of 2016.
Regarding the Bettini et al. (2017) study and the technical hearing in the Open ANS Plenary,1 the
Panel noted that:
• the TiO2 test materials were prepared following the generic Nanogenotox dispersion protocol,
which involved coating of the particles with bovine serum albumin (BSA) and ultrasonication.
This protocol was designed to prevent agglomeration of the nanoparticles and was especially
developed for the hazard identiﬁcation of nanoparticles in suspension;
• the administration of TiO2 (E 171) by gavage or drinking water is not fully representative of
the use of the food additive E 171 in food. This could introduce some uncertainties in the
extrapolation of the results of this study to the assessment of the food additive, because
interactions with the food matrix may not occur;
• the effects observed on immunomodulation/inﬂammation were in line with those occurring in
the very early steps of the development of an inﬂammatory/immunological reaction. Variations
of different biomarkers were low (within 10–20% change), thus questioning the biological
relevance of the results, also taking into account the lack of historical data for that kind of
study;
• BSA coated on particles of TiO2 (E 171) could itself trigger an immunologic and/or allergic
reaction;
• although the model used to investigate the effects of TiO2 (E 171) in the development of
putative preneoplastic lesions in the colon was well described, the Panel noted some
limitations, such as the use of a single marker;
• the presence of aberrant crypt foci (ACF) in the absence of an initiator is unusual, but in this
study ACF were observed in the colon of a few animals treated with TiO2 (E 171) alone;
• the initiation potential of TiO2 reported in this study was not observed in another study using
TiO2 (E 171) (Urrutia-Ortega et al., 2016);
1 https://www.efsa.europa.eu/en/events/event/180515
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• a publication by Wijnands et al. (2004), showed that the number and size of ACF induced by
different dietary compounds such as wheat bran, curcumin, rutin or benzyl isothiocyanate,
were not predictive for the ultimate number of colorectal tumours. Wijnands et al. (2004)
concluded that ‘the number and size of ACF were not considered to be suitable as biomarkers
for colorectal cancer’, whereas the expression of some tumour-related genes (e.g.
metalloproteinase 1; TIMP-1) ‘correlated well with the effects of dietary compounds on the
ultimate tumour yield’.
Overall, based on the data provided in the Bettini et al. publication, and the negative results of the
carcinogenicity studies in mice and rats performed by NCI (1979), the Panel considered that the new
ﬁndings were not sufﬁcient to raise a concern on the potential initiation or promotion properties of
TiO2 (E 171) on colon carcinogenesis.
Regarding the Proquin et al. (2017) study and the technical hearing in the Open ANS Plenary,1 the
Panel noted that:
• this in vitro study adds to a number of studies which provided some evidence of reactive
oxygen species (ROS) formation and in vitro genotoxicity by microparticulate (MP) TiO2 and
TiO2 nanoparticles (NP) in a variety of cell lines of human and rodent origin (as reported in
EFSA ANS Panel, 2016). These authors reported for the ﬁrst time genotoxic activity in vitro in a
Comet assay and cytokinesis-block micronucleus assay using the food additive TiO2 (E 171).
The Panel noted that, in view of the composition of TiO2 (E 171) (containing around 40% of
nanoparticles by number), and of the available evidence of genotoxicity in vitro of both TiO2
MP and TiO2 NP, a genotoxic activity of E 171 under in vitro conditions could already be
anticipated. In this respect, the Panel also noted that overall negative results were obtained in
studies in vivo with both TiO2 NP and MP (EFSA ANS Panel, 2016), indicating that TiO2 MP and
NP, and consequently E 171, did not raise concern for in vivo genotoxicity;
• two cell lines derived from human colon (adeno)carcinomas were selected as model systems to
investigate the possible implication of ROS generation and genotoxicity in the promoting
activity of TiO2 (E 171) on chemically-induced colon carcinogenicity in mice reported in a
previous study (Urrutia-Ortega et al., 2016). Based on the discussion at the technical hearing
at the open Plenary, the Panel noted that this model appeared suitable for hazard
characterisation but not for the purpose of risk assessment;
• undifferentiated Caco-2 cells, harvested after only 3 days of culture, were used for the
assessment of DNA damage induced by TiO2. As to the relevance of the cell system used for
hazard characterisation, the Panel noted that another recent in vitro study highlighted a
comparable lower incorporation of TiO2 in differentiated compared to undifferentiated Caco-2
cells, and no induction of DNA damage in differentiated Caco-2 cells monolayers exposed to
TiO2 NP was observed (Vila et al., 2018). The Panel also noted that under in vivo conditions,
the uptake of TiO2 particles (including E 171) may be substantially decreased by the mucus
layer of the intestinal epithelium (Garcia-Rodriguez et al., 2018);
• concerning the claimed colocalisation of TiO2 (E 171) with ‘kinetochore poles, mitotic genome
and a-tubulin’, the Panel noted that no clear conclusion can be drawn from the ﬁgures presented,
which may be either indicative of a true colocalisation and functional interaction, or arise from the
unspeciﬁc overlap of TiO2 particles on cellular structures in the microscopic preparation.
Overall, the Panel considered that the results reported in the Proquin et al. (2017) study may be
useful for an evaluation of the hazard of TiO2 NP under the speciﬁc conditions of the study protocol,
including the cell model used and the conditions of culture. However, the Panel also considered that
the relevance of the results for risk assessment of the food additive E 171 has not been established.
During the discussion at the technical hearing at the open Plenary, one of the authors mentioned
that consistent results appeared to be observed in mouse colon in ongoing in vivo transcriptomics
studies. The Panel considered that these studies could be evaluated when completed, and if deemed
necessary, the overall database reassessed considering the entire literature available at that time.
Regarding the Guo et al. (2017) study and the technical hearing in the Open ANS Plenary,1 the
Panel noted that:
• the study was performed with engineered TiO2 NP and not with TiO2 as a food additive;
• the TiO2 NP suspension was sonicated to minimise agglomeration and/or aggregation which
may not occur in more realistic environments;
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• in addition to the transmission electron microscopy (TEM) analysis of primary particles, the
dynamic light scattering (DLS) results suggested that the hydrodynamic sizes were
considerably larger which suggested that the TiO2 NP may be aggregated and agglomerated;
• the authors assumed that all ingested particles would be in contact with the wall surface but
without considering the potential interaction of nanoparticles with luminal contents, e.g. their
estimated number of nanoparticles was comparable with the number of microorganisms per
gram of intestinal contents (ranges from 105–6 in intestine to 1013 in colon);
• the glycocalyx on cultured Caco-2 cells is different from that on normal human intestinal cells;
• the cells were rinsed in phosphate-buffered saline (PBS) before exposing them to TiO2 NP
which could alter the glycocalyx and the interactions of Caco-2 cells with TiO2 NP;
• changes in the expression of proinﬂammatory genes seen after 5-days of treatment with TiO2
NP were small, not dose-related and uneven;
• no information was available about possible markers of inﬂammation such as production/
secretion of cytokines, changes in the expression of membrane antigens;
• no transport of TiO2 NP across the Caco-2/Ht29 MTX monolayers was reported;
• as more physiological conditions were approached the effects were attenuated, and it was
difﬁcult to extrapolate these results to the in vivo situation.
Regarding the Heringa et al. (2016) study and the technical hearing in the Open ANS Plenary,1 the
Panel noted that:
• the National Institute for Public Health and the Environment (RIVM) provided this and two
other unpublished reports at the time of the re-evaluation of the TiO2 (E 171) as a food
additive in 2016 (EFSA ANS Panel, 2016);
• these unpublished studies did not affect the Panel’s conclusions drawn from the available
database at that time;
• Heringa et al. assumed that, although there was no information available on the absorption of
TiO2 particles, any toxicity was caused by TiO2 NP;
• the conclusions of the authors that, because of uncertainties and assumptions in their analysis,
further studies would be needed, for example, on the actual concentration of nano-TiO2 in
human organs and on the effects in liver and the reproductive system after chronic exposure
to well-characterised TiO2 NP;
• data on reproductive toxicity were scarce;
• the results on effects on testosterone levels in the two studies (Jia et al., 2014; Tassinari et al.,
2014) used by Heringa et al. (2016) were contradictory;
• signiﬁcant uncertainties were associated with extrapolation from short term to lifetime
exposures;
• although the application of uncertainty factors for extrapolation from short-term studies is a
policy choice, Heringa et al. used uncertainty factors from REACH rather than those
recommended by the EFSA SC (EFSA Scientiﬁc Committee, 2012);
• in deriving acceptable Margin of internal Exposure (MoEi), the kinetic element of the inter- and
intraspecies uncertainty factors was only removed from the interspecies but not from the
intraspecies uncertainty factor;
• effects seen in short-term studies with no functional effect in longer term studies are usually
not considered a robust basis for risk assessment.
Overall, the Panel considered that the aforementioned evaluations and considerations indicated that
there was signiﬁcant uncertainty in the assessment by Heringa et al. (2016) and noted that there was not
a weight of evidence analysis of the whole database on E 171. The Panel considered that the assessment
was consistent with a hazard from TiO2 NP when dosed as in the selected studies but the relevance to
nanoparticles in a food matrix could not be assessed. The Panel concluded that the additional studies
called for in its 2016 opinion should provide a more robust basis for addressing the reported effects in
reproductive organs in the studies used by Heringa et al. (2016).
Based on the evaluation of the four studies concerning the potential adverse health effects of
titanium dioxide the Panel considered that:
• the results of the Bettini et al. (2017) study did not provide enough justiﬁcation for a new
carcinogenicity study, but, should additional useful mechanistic information become available,
this could be reconsidered in future;
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• the new in vitro ﬁndings in the study by Proquin et al. (2017) did not modify the conclusion on
the genotoxicity of TiO2 as stated in the previous EFSA opinion (EFSA ANS Panel, 2016) on the
safety of TiO2 (E 171) when used as a food additive;
• the effects of engineered TiO2 nanoparticles reported by the Guo et al. (2017) study were of
uncertain biological signiﬁcance and therefore of limited relevance for the risk assessment of
the food additive TiO2 (E 171);
• there was signiﬁcant uncertainty in the risk assessment performed by Heringa et al. (2016),
which did not include a weight of evidence analysis of the whole database;
• the four studies evaluated, highlighted some concerns but with uncertainties, therefore their
relevance for the risk assessment was considered limited and further research would be
needed to decrease the level of uncertainties.
Overall, three of the studies assessed in this opinion reported that TiO2 was able to induce various
effects in in vitro and in vivo models. These studies may be useful for hazard identiﬁcation of TiO2.
The Panel considered that the limited relevance of the protocols of these studies to the use of E 171
under realistic conditions in food, hampered the use of the data in the risk assessment of the food
additive E 171. In the fourth study by Heringa et al. (2016), numerous assumptions were made, which
resulted in large uncertainty in their conclusion.
More research exploring the possible effects observed in three of the four studies could address
their applicability to the risk assessment of the food additive E 171 under realistic conditions of use.
Altogether, the Panel concluded that the outcome of the four studies did not merit re-opening the
existing opinion of EFSA related to the safety of TiO2 (E 171) as a food additive.
The Panel recommended that:
• in order to substantiate the observations in the Bettini et al. (2017), biomarkers for putative
preneoplastic lesions in the colon as additional parameters should be examined in the
extended one-generation reproductive toxicity study recommended by EFSA (EFSA ANS Panel,
2016);
• further studies on TiO2 NP should include administration in a food matrix.
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1. Introduction
Upon request of the European Commission (EC), the EFSA Food Additive and Nutrient sources
added to Food (ANS Panel) has assessed four new publications (Heringa et al., 2016; Bettini et al.,
2017; Guo et al., 2017; Proquin et al., 2017) concerning the potential adverse health effects of
titanium dioxide (TiO2). The Panel is aware of other publications that have been published after the
publication of the scientiﬁc opinion on the re-evaluation of TiO2 (E 171) as a food additive in 2016
(EFSA ANS Panel), but these were not taken into consideration in this evaluation, which is restricted to
the four publications included in the EC request.
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
The use of food additives is regulated under the European Parliament and Council Regulation (EC)
No 1333/2008 on food additives.2 Only food additives that are included in the Union list, in particular
in Annex II to that regulation, may be placed on the market and used in foods under the conditions of
use speciﬁed therein. Moreover, food additives shall comply with the speciﬁcations as referred to in
Article 14 of that Regulation and laid down in Commission Regulation (EU) No 231/20123.
Titanium dioxide is authorised for use as a food additive (food colour) in the Union. Since titanium
dioxide (E 171) was permitted in the Union before 20 January 2009, it belongs to the group of food
additives which are subject to a new risk assessment by the European Food Safety Authority (EFSA),
according to Commission Regulation (EU) No 257/20104, and in line with the provisions of Regulation
(EC) No 1333/2008.
The re-evaluation of titanium dioxide as a food additive (E 171) was completed by EFSA in June 2016
and a scientiﬁc opinion was published in September 2016 (EFSA ANS Panel, 2016). In that opinion, EFSA
concluded, on the basis of the available evidence, that titanium dioxide (E 171) when used as a food
additive does not raise a concern with respect to genotoxicity and that it is not carcinogenic after oral
administration. However, several data gaps were also identiﬁed by EFSA in the opinion. These warranted
a follow-up by the European Commission5 and new scientiﬁc evidence is being generated by interested
parties in order to address the uncertainties highlighted by EFSA in its scientiﬁc opinion.
Nevertheless, authorised food additives should be kept under continuous observation and must be
re-evaluated whenever necessary in the light of changing conditions of use and new scientiﬁc
information.
Four new scientiﬁc articles (Heringa et al., 2016; Bettini et al., 2017; Guo et al., 2017; Proquin
et al., 2017a) describing a potential adverse health effect of titanium dioxide used as a food additive
(E 171) have recently been published, after the adoption and publication of EFSA’s scientiﬁc opinion on
the re-evaluation of titanium dioxide as a food additive (E 171) in 2016. Consequently, the European
Commission has decided to consult EFSA on this matter.
1.1.2. Terms of Reference
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20026, the European Commission
requests the European Food Safety Authority (EFSA) to provide a scientiﬁc opinion in relation to four
new studies on the potential toxicity of titanium dioxide used as a food additive (E 171). In particular,
EFSA is requested to carry out a scientiﬁc evaluation of those studies and to indicate whether they
would merit re-opening the existing opinion of EFSA related to the safety of titanium dioxide (E 171)
as a food additive.
2. Data and methodologies
2.1. Data
The data considered in this scientiﬁc opinion are those identiﬁed by the requestor of this mandate,
which concerns the four publications identiﬁed in the background to this request:
2 OJ L 354, 31.12.2008, p. 16.
3 OJ L 83, 22.3.2012, p. 1.
4 OJ L 80, 26.3.2010, p. 19.
5 https://ec.europa.eu/food/sites/food/ﬁles/safety/docs/fs-iron_titanium_dioxide-overview-deadlines-milestones-20170730.pdf
6 OJ L 31, 1.2.2002, p. 1.
Evaluation of four studies on titanium dioxide (E 171)
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2018;16(7):5366
• Bettini et al. (2017). Food-grade TiO2 impairs intestinal and systemic immune homeostasis,
initiates preneoplastic lesions and promotes aberrant crypt development in the rat colon. Sci
Rep. 2017, 7:40373.
• Proquin et al. (2017). Titanium dioxide food additive (E 171) induces ROS formation and
genotoxicity: contribution of micro and nano-sized fractions. Mutagenesis, 2017, 32, 139–149.
• Guo et al. (2017). Titanium dioxide nanoparticle ingestion alters nutrient absorption in an
in vitro model of the small intestine. NanoImpact, 5, 70–82, 2017.
• Heringa et al., 2016. Risk assessment of titanium dioxide nanoparticles via oral exposure,
including toxicokinetic considerations. Nanotoxicology Vol. 10, Iss. 10, 2016.
When necessary for the interpretation of the results of the studies, also references cited in the
publications above have been retrieved and assessed.
Additional information was provided by the authors of the four publications upon request of the
Working Group (Appendices B, C, D and E).
The authors of the four publications above were invited to join the ANS plenary meeting open to
observers on 16 May 2018 as hearing experts,1 in order to present an overview on their studies and to
answer questions and to comment on their ﬁndings. The main points and outcome of that discussion
have been considered in developing this document.
2.2. Methodologies
In order to address this mandate, the approach described in the ‘Scientiﬁc opinion on scientiﬁc
motivations and criteria to consider updating EFSA scientiﬁc assessments’ adopted by the EFSA
Scientiﬁc Committee in 2017 (EFSA Scientiﬁc Committee, 2017a) was followed.
In particular, with respect to the approach followed for reaching conclusions on whether there is a
need to update the previous ANS Panel scientiﬁc opinion, the new scientiﬁc evidence has been
evaluated against the following criteria:
• Are the new data relevant to the safety of TiO2 used as a food additive?
• Does the new scientiﬁc evidence address important data gaps previously identiﬁed?
• Are the new data likely to change the overall conclusions of the scientiﬁc opinion (EFSA ANS
Panel, 2016), in a weight of evidence approach?
The screening of the new data has been carried out by a Working Group (WG) under the
responsibility of the EFSA ANS Panel, which was involved in the original assessment.
2.2.1. Bettini et al. (2017). Food-grade TiO2 impairs intestinal and systemic
immune homeostasis, initiates preneoplastic lesions and promotes
aberrant crypt development in the rat colon
In 2017, EFSA was informed that the French Food Safety Agency (ANSES) was asked to assess the
publication by Bettini et al. (2017). EFSA collaborated with ANSES with respect to their ongoing
assessment, following the provisions of Article 30(1) and (2) of the Regulation EC No 178/2002, in
order to identify at an early stage any potential source of divergence between the conclusions of EFSA
and ANSES opinions. In March 2017, a technical hearing was organised by ANSES with the authors of
this study. ANSES experts and staff, EFSA staff, two experts from the ANS Panel and one expert from
the EFSA FEEDAP Panel participated in this meeting and the joint scientiﬁc discussion that followed.
The ANS Panel was informed about the outcome of those discussion and that the main conclusions of
the ANSES WG of experts were going to be included in a scientiﬁc opinion of ANSES, which was
published in April 2017 (ANSES, 2017; an English translation of the conclusions of the ANSES WG of
experts is provided in Appendix A). The Panel agreed with ANSES that the publication by Bettini et al.
(2017) would not justify reopening the EFSA opinion on TiO2 (E 171) (EFSA ANS Panel, 2016).
Bettini et al. (2017) investigated the potential effects of titanium dioxide (TiO2, E 171, containing
44.7% by number of nanoparticles as measured by transmission electron microscopy (TEM))7 on
inﬂammation, genotoxicity and initiation/promotion of putative preneoplastic colon lesions in rats.
In a ﬁrst set of toxicological studies, adult male Wistar rats (10 rats/group) were administrated
nano titanium dioxide (NM-105) (JRC, 2014), or TiO2 (E 171) or vehicle (water), by gavage at a dose
of 10 mg/kg body weight (bw) per day, for 7 days. TiO2 test materials were prepared following the
7 One commercially available titanium dioxide food additive (E 171) provided from a French supplier of food colouring.
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generic Nanogenotox dispersion protocol, which involved coating of the particles with bovine serum
albumin (BSA) and ultrasonication.
In a second series of experiments, adult male Wistar rats (11–12 rats/group) were treated with or
without 1,2-dimethylhydrazine (DMH) (180 mg/kg, one single intraperitoneal (i.p.) injection) to initiate
colon carcinogenesis, and were then administered with TiO2 (E 171) at 200 lg or 10 mg/kg bw per
day in drinking water, for 100 days. Control animals (n = 12) received water only.
The dispersion state of TiO2 particles was determined in the luminal content of the jejunum and
colon (4 h after the administration of a single dose of TiO2 (E 171)). The results indicated that TiO2
particles did not re-agglomerate in vivo when transiting along the gastrointestinal tract. TiO2 particles
were found in the Peyer’s Patches (PP) of the small intestine, colonic mucosa and liver of rats
administered TiO2 (E 171) by gavage for 7 days, but not in the controls. In the same treated rats,
titanium was detected in the gut lumen, PP, colon mucosa and liver. A similar distribution pattern in PP
(highest in the nuclei) was found in animals treated with NM-105 or TiO2 (E 171). No signiﬁcant
changes in the gut permeability were found, suggesting that the particle absorption did not result from
a dysfunction of the epithelial barrier integrity. No increase in DNA damage was found in PP of rats
treated with TiO2 (E 171) or NM-105.
A signiﬁcant increase in dendritic cells (DC) frequency in PP was found after 7 days in TiO2 (E 171)
or NM-105 treated rats, but not after 100 days in rats exposed to TiO2 (E 171) in drinking water,
indicating that this effect was transient. Other regulatory T cells (i.e. Tregs, expressing the biomarkers
CD4+, CD25+, FoxP3+) were decreased in animals treated with TiO2 (E 171) for 7 or 100 days, and
this was concomitant with a decrease in T helper (Th) cells (i.e. CD4+; CD25+). A decrease in
interferon-c (IFN-c) secretion in the PP, and an increase in IFN-c secretion and interleukin-17 (IL-17)
level in the spleen, were reported in all treated animals.
In rats, i.p. injected with a single dose of 180 mg/kg bw DMH and treated with TiO2 (E 171) at 10
mg/kg bw per day for 100 days in drinking water, the total number of aberrant crypts per colon as well
as the number of large aberrant crypt foci (ACF) per colon (i.e. more than three aberrant crypts per
ACF) was signiﬁcantly increased compared to controls or the 200 lg/kg bw per day group. No ACF
were observed in the colon of control rats (without initiation with DMH). However, in the TiO2 (E 171)
group without initiation with DMH, 4 out of 11 animals spontaneously developed one to three ACF per
colon, and 3 out of 4 of these rats developed lesions of 1–3 aberrant crypts per ACF, whereas one rat
developed one ACF consisting of 12 aberrant crypts. In the colonic mucosa of the treated animals with
TiO2 (E 171), a signiﬁcant increase of tumour necrosis factor-a (TNF-a), IL-8 and IL-10 was also
observed compared to the controls. There was no evidence of inﬂammasome activation in the mucosa.
Altogether, according to the authors, ‘food-grade TiO2 particles cross the gut barrier and reach the
liver without altering intestinal permeability or causing DNA damage in Peyer’s patches’; ‘food-grade
TiO2 particles affect dendritic cell frequencies and T cell populations in the Peyer’s patches and cause
imbalances in intestinal and systemic immune responses’; and ‘food-grade TiO2 particles initiate and
promote preneoplastic lesion formation in the colon and induce mucosal low-grade inﬂammation’.
2.2.2. Proquin et al. (2017). Titanium dioxide food additive (E 171) induces ROS
formation and genotoxicity: contribution of micro and nano-sized
fractions
Proquin et al. (2017) evaluated cytotoxicity, reactive oxygen species (ROS) production and in vitro
genotoxicity of TiO2 in two human colon cancer cells lines (Caco-2 and/or HCT116) using three
different materials: TiO2 (E 171, containing 39% nanoparticles by number; analysed by scanning
electron microscopy (SEM)),8 microparticulate TiO2 (MP, average size 535 nm, analysed by TEM) and
TiO2 nanoparticles (NP, 10–30 nm, analysed by SEM). For the experiments, particles were dispersed at
a concentration of 1 mg/mL in Dulbecco’s modiﬁed Eagle’s medium (DMEM) with 0.05% BSA, Hank’s
balanced salt solution (HBSS), or McCoy medium with 10% fetal bovine serum (FBS) and sonicated 30
min. Characterisation of hydrodynamic size distribution and zeta potential by dynamic light scattering
(DLS) showed that serum, and to a lower extent BSA, reduced the agglomeration of particles after
sonication, improving the dispersion and stability of suspensions. Cytotoxicity was evaluated in Caco-2
cells by the trypan blue viability assay after 24 h exposure to 1–1,000 lg/mL (equivalent to 0.143–143
lg/cm2) of TiO2 (all three materials) dispersed in DMEM plus 0.05% BSA. Cytotoxicity was observed at
1,000 lg/mL with all three materials and at 100 lg/mL with TiO2 (E 171) only; the two lowest doses
8 Sensient Technologies company (Mexico).
Evaluation of four studies on titanium dioxide (E 171)
www.efsa.europa.eu/efsajournal 10 EFSA Journal 2018;16(7):5366
(1 and 10 lg/mL) were non-cytotoxic and were selected for further experiments with Caco-2 cells. The
capacity of TiO2 (all three materials) to generate ROS was investigated by electron spin resonance
(ESR)/paramagnetic resonance spectroscopy under cell-free conditions and in Caco-2 cells. In cell-free
experiments, both TiO2 (E 171) (at 1,000 lg/mL) and TiO2 NP (at 100 and 1,000 lg/mL) generated
ROS when suspended in HBSS, but ROS generation was inhibited in medium plus 0.05% BSA,
suggesting a scavenging or inhibitory effect by the protein corona. Differently from what observed
in cell-free conditions, only TiO2 MP (1–10 lg/mL) signiﬁcantly increased intracellular ROS levels in
Caco-2 cells. Exposure of Caco-2 cells to TiO2 (E 171), as well as to TiO2 NP and TiO2 MP (24 h, 1–10
lg/mL) induced signiﬁcant, although not dose-related, increases of DNA damage in comet assays. The
potential of TiO2 (E 171) to affect chromosome integrity and/or segregation was evaluated with the
cytokinesis-block micronucleus assay in HCT116 cells, which show a more stable karyotype compared
to Caco-2 cells and are more suitable for micronucleus analysis. Cells were exposed for 24 h to 50, 100
and 500 lg TiO2 (E 171)/mL: no cytotoxicity was observed in treated cultures, which showed a
statistically signiﬁcant and dose-related increases of micronucleated cells (up to threefold over negative
control). Finally, the capacity of TiO2 (E 171) to interfere with mitotic chromosome segregation in
HCT116 cells was preliminary investigated by the immunostaining of HCT116 cells with a mouse
monoclonal anti-a-tubulin antibody. According to the study authors, TiO2 (E 171) ‘seemed to interact
with the centromere region of kinetochore poles during mitosis’, and ‘appear to co-localize with
a-tubulin’, suggesting an interaction with chromosomes or the mitotic apparatus.
The authors of the study concluded that this was the ﬁrst demonstration of the induction of ROS
formation and DNA damage in cultured colon cells by TiO2 (E 171), and that this would raise concerns
about potential adverse effects associated with TiO2 (E 171) in food.
The authors also made a tentative estimation of exposure of human colon cells to TiO2 following
the ingestion of 1 mg TiO2/kg bw per day using their speciﬁed exposure scenario and assumptions.
The authors estimated that the concentration of TiO2 reaching colon cells would be in the same order
of magnitude as the concentrations of TiO2 used in the in vitro experiments (1–10 lg/mL).
2.2.3. Guo et al. (2017). Titanium dioxide nanoparticle ingestion alters nutrient
absorption in an in vitro model of the small intestine
Guo et al. (2017) assessed the effect of 4 h and 5 days exposure to TiO2 nanoparticles (NP, 20–40
nm, analysed by TEM), using an in vitro Caco-2/HT29-MTX cell culture model, on the intestinal barrier
function, nutrient absorption, formation of ROS, and proinﬂammatory signal. In vitro doses of TiO2 NP
were formulated to represent potential real-life exposure. The daily intake of TiO2 NP has been
estimated by the authors to be 1012–1014 NP per day (approximately 1011–1013 particles per meal;
Lomer et al., 2002). Low (106 particles/cm2), medium (108 particles/cm2) and high (1010 particles/cm2)
concentrations of TiO2 NP were used for the 4 h exposure. The authors estimated the concentrations
of nanoparticle by dividing the estimated number of nanoparticles by the surface area of the small
intestine. The daily dose used in the 5 days exposure was three times the single dose concentration.
The 4 h exposure of the cells to TiO2 NP did not show any signiﬁcant difference on the tight junction
functionality compared to the control; however, 5 days exposure (at the three concentrations)
enlarged the gap between cells and increased the tight junction permeability. The authors reported
that despite efforts to measure TiO2 transport to the basolateral chamber with ICP-MS, no TiO2
transport across the Caco-2/HT29-MTX monolayers was observed.
Both the 4 h and 5 days exposure (at the three concentrations) resulted in an increase in ROS
production in the intestinal epithelial cells, as well as in a decrease in iron and zinc transport and
uptake. Only the 5 days exposure (high concentration) to TiO2 NP signiﬁcantly reduced the fatty acid
uptake, whereas both the 4 h and 5 days exposure (medium and high concentrations) altered the
brush border membrane enzyme functionality by signiﬁcantly increasing the intestinal alkaline
phosphatase (IAP) activity. Gene expression of iron transport proteins as well as of proinﬂammatory
cytokines (i.e. IL-8, TNF-a, nuclear factor kappa B (NF-kb)) was altered, in response to 5 days
exposure to TiO2 NP.
According to the authors, the results of this study suggested that physiologically relevant
concentrations of TiO2 NP may affect the ROS generation in an in vitro model of the small intestine,
inducing proinﬂammatory signalling, which in turn could have an impact on the intestinal epithelial
cells function.
Evaluation of four studies on titanium dioxide (E 171)
www.efsa.europa.eu/efsajournal 11 EFSA Journal 2018;16(7):5366
2.2.4. Heringa et al. (2016). Risk assessment of titanium dioxide nanoparticles
via oral exposure, including toxicokinetic considerations
The publication by Heringa et al. (2016) is not a primary research study but rather a risk
assessment of the oral intake of TiO2 nanoparticles (TiO2 NP) based on data reported in other
publications. The assessment was performed using two approaches: a ﬁrst one based on human
dietary intake estimation (external dose) combined with the lowest no observed adverse effects levels
(NOAEL) from the animal toxicity studies, and a second one based on internal, modelled dose.
Both approaches start with an estimation of human dietary intake of TiO2 NP from food products,
food supplements and toothpaste in the Dutch population, as calculated by Rompelberg et al. (2016).
Only high level (P95) intake of TiO2 NP were considered for this risk assessment, ranging from 0.74
lg/kg bw per day in the elderly (70 years and older) to 4.2 lg/kg bw per day in 2- to 6-year-old
children. The P95 intake of TiO2 NP for the population aged 7–69 years was estimated to be 1.6 lg/kg
bw per day. Based on the values above, the lifelong daily intake of TiO2 NP for the P95 of the
population was calculated to be 1.7 lg/kg bw per day.
The Panel noted that the estimated intake of TiO2 from the Rompelberg et al. (2016) study is lower
than the estimated exposure calculated by EFSA for TiO2 (E 171), which is most probably due to the
different concentration levels of TiO2 assumed in food products. In addition, the food categories
considered in both the exposure assessments were different. Rompelberg et al. (2016) also took into
account intakes of TiO2 from its use in toothpaste. With respect to the calculation of exposure to TiO2
nanoparticles, it was noted that the ANS Panel considered that 3.2% (by mass) of the TiO2 (E 171)
were nanoparticles, according to information provided by industry (EFSA ANS Panel, 2016), whereas in
the Rompelberg et al. (2016) study the percentage of nanoparticles in TiO2 was considered to be
0.31% (by mass).
Four toxicity studies (NCI, 1979; Wang et al., 2013; Jia et al., 2014; Tassinari et al., 2014) were
identiﬁed as pivotal for the risk assessment by the Heringa et al. All of them, with the exception of the
study by Wang et al. (2013), had been already considered by the Panel in the re-evaluation of TiO2
(E 171) as a food additive (EFSA ANS Panel, 2016).
According to Heringa et al. (2016), using the traditional approach for risk assessment, the intake
was used for deriving Margins of external Exposure (MoEe) by dividing the NOAEL or the lowest
observed adverse effect level (LOAEL) from their identiﬁed four key toxicity studies (see more details
in Table 1 of Heringa et al., 2016) by this intake estimate.
The study by Wang et al. (2013) was used by Heringa et al. (2016) to derive a Point of Departure
(PoD) for effects on the liver, equal to a NOAEL of 10 mg/kg bw per day. This value, divided by the
estimated intake of TiO2 NP for the general population of 1.7 lg/kg bw per day resulted in a MoEe of
5,882, i.e. nearly 10-fold higher than the value considered to be acceptable by the authors (> 600).
Other MoEes were calculated also for the other LOAELs and NOAELs identiﬁed from the other three
key toxicity studies reported above, all of them resulting in acceptable MoEes with the exception of the
effects on the ovary observed in the study by Tassinari et al. (2014), for which Heringa et al. (2016)
deﬁned an acceptable MoEe of 3,000 compared to the 300–700 in the three other key studies. Heringa
et al. (2016) however, acknowledged that owing to the short duration (5 days) of the Tassinari et al.
(2014) study, extrapolation of the results to chronic intake introduces important uncertainties and that
the ﬁndings would need to be conﬁrmed in long-term studies.
In their second approach for the risk assessment, Heringa et al. (2016) used a kinetic model, based
on the data by Geraets et al. (2014) obtained after intravenous (i.v.) administration of TiO2 NP
adjusted for a better ﬁt for the prediction of oral absorption. The authors acknowledged that although
they considered this to be the best available model for oral exposures, there might be some inaccuracy
in the results due to the differences in toxicokinetic behaviour between the two routes of
administration. This kinetic model was used to calculate internal organ doses for the selected rat
toxicity studies. However, the authors noted that the predicted values in rat liver were higher than
measured ones following oral absorption in the Geraets et al. (2014) study by 1.5- to 4-fold, which
was ascribed to using worst case assumptions in the model.
The rat kinetic model was then converted into a human model using physiological data and
allometric scaling of kinetic parameters from rat to human. Organ concentrations in humans were
estimated using the intake data for the three different age groups from the Rompelberg et al. (2016)
study. According to this second approach, the estimated organ concentrations at which effects of TiO2
NP were observed in the animal studies were compared to the estimated human organ concentrations
resulting in Margins of internal Exposure (MoEi). The MoEi calculated by the authors at three ages (20,
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40 and 80 years) were then compared to estimated acceptable MoEi derived from the key four studies.
For the latter, Heringa et al. (2016) acknowledged that these values have not been subject to
international review and, therefore, should only be considered for the sole purpose of their evaluation.
There was a decrease in the MoEi with age for all estimated organs except the liver. By using this
approach, for the three studies in which TiO2 NP were tested, the estimated MoEi were lower than the
derived acceptable MoEis by Heringa et al. (2016). The acceptable MoEi values were deﬁned by
Heringa et al. (2016) using factors of 2.5 for interspecies and 10 for intraspecies differences with
default factors for extrapolation for the duration of exposure to chronic exposure and LOAEL to NOAEL
extrapolation from REACH Guidance (ECHA, 2012). Heringa et al. (2016) considered that these MoEis
indicated a potential risk for effects on the target organs of these studies (liver, testes and ovary). In
contrast, assuming a fraction of 0.31% nanoparticles by weight in the test material, the estimated
MoEi from the 2-year carcinogenicity study (NCI, 1979) was higher than the acceptable estimated
MoEi, indicating a risk was unlikely.
Heringa et al. (2016) also noted that for all the three studies conducted with TiO2 NP, the predicted
levels in human organs were still lower than the organ levels estimated from the kinetic model that
were related to toxicity in the corresponding animal studies, the only exception being the predicted
levels in the human ovaries. As for the other approach, also in this case, Heringa et al. (2016)
considered that extrapolation of the data from the short-term study by Tassinari et al. (2014)
represented a ‘rather large’ source of uncertainty. Heringa et al. (2016) included a discussion of the
uncertainties and assumptions used in the model and the risk assessment.
3. Discussion
As requested in this mandate by the EC, in this opinion the Panel concentrated on the evaluation of
four publications concerning the potential adverse health effects of TiO2 (Heringa et al., 2016; Bettini
et al., 2017; Guo et al., 2017; Proquin et al., 2017). The Panel was aware of these publications and of
a number of other new publications on TiO2 since its last opinion (EFSA ANS Panel, 2016), but these
other publications were not taken into consideration in the present evaluation. Individual publications
should be assessed in respect to the whole dataset available, using a weight of evidence approach
(EFSA Scientiﬁc Committee, 2017b). A proper evaluation of the safety of titanium dioxide as a food
additive would require considering all data available and not only selected data. The EFSA SC also
provided Guidance on when the database should be re-evaluated in light of new evidence (EFSA
Scientiﬁc Committee, 2017a).
The re-evaluation of TiO2 (E 171) for use as a food additive had been completed by the EFSA ANS
Panel in June 2016, and a scientiﬁc opinion published in September 2016 (EFSA ANS Panel, 2016). The
Panel concluded that the use of TiO2 as a food additive did not raise a genotoxic concern. From a
carcinogenicity study with TiO2 in mice and in rats (NCI, 1979), the Panel identiﬁed the lowest NOAEL
which was 2,250 mg TiO2/kg bw per day for males from the rat study, the highest dose tested in this
species and sex. However, the Panel was unable to reach a deﬁnitive conclusion on the reproductive
and developmental toxicity endpoints, due to the lack of an extended 90-day study or a
multigeneration or extended one-generation reproduction toxicity study with the food additive (E 171).
Therefore, the Panel did not establish an acceptable daily intake (ADI). Taking into account the
toxicological database available at that time and the considerations that the absorption of orally
administered TiO2 was extremely low, the Panel considered that the margins of safety (MoS) calculated
from the NOAEL of 2,250 mg TiO2/kg bw per day and the exposure calculated from the reported use/
analytical levels of TiO2 (E 171) would not be of concern. The Panel concluded that once deﬁnitive and
reliable data on the reproductive toxicity of E 171 were available, the full dataset would enable the
Panel to establish a health-based guidance value (ADI).
From the data provided from interested parties and the ones publicly available, the Panel noted
that the fraction of titanium dioxide nanoparticles (with one dimension less than 100 nm) measured in
E 171 is method-dependent (EFSA ANS Panel, 2016). The Panel further noted that there were no set
limits for the particle size of titanium dioxide in the EU speciﬁcations (Commission Regulation (EU) No
231/2012), and recommended that the characterisation of the particle size distribution as well as the
percentage (in number and by mass) of particles in the nanoscale present in the food additive E 171
should be included among the EU speciﬁcations.
The EC, as part of the follow up activities for those food additives whose safety re-evaluation by
EFSA was hindered by limited data availability but which were not expected to pose an immediate food
safety concern, launched a call for data on TiO2 (E 171) inviting interested business operators to
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generate the additional data requested by a certain deadline.9 Following this call for data, interested
parties have committed to provide the requested information according to a deﬁned timeline. In
particular, data on particle size and particle size distribution for TiO2 (E 171) would be submitted by
June 2018, whereas a dietary Extended One-Generation Reproductive Toxicity Study with TiO2 (E 171)
in rats (carried out according to the current OECD guidelines and with TiO2 (E 171) complying with the
EU speciﬁcations and including a characterisation of the particle size distribution) would be generated
by August 2019. The study design should include cohort 1 (extension by mating of F1 animals to the
F2 generation), cohort 2 (for developmental neurotoxicity) and cohort 3 (for developmental
immunotoxicity).
The Panel has assessed the four publications as requested in the last mandate from the EC and
made the following speciﬁc comments on each individual studies which have been considered in the
context of the conclusions of the EFSA opinion of 2016.
Regarding the Bettini et al. (2017) study and the technical hearing in the Open ANS Plenary,1 the
Panel noted that:
• the TiO2 test materials were prepared following the generic Nanogenotox dispersion protocol,
which involved coating of the particles with BSA and ultrasonication. This protocol was
designed to prevent agglomeration of the nanoparticles and was especially developed for the
hazard identiﬁcation of nanoparticles in suspension;
• the administration of TiO2 (E 171) by gavage or drinking water is not fully representative of
the use of the food additive E 171 in food. This could introduce some uncertainties in the
extrapolation of the results of this study to the assessment of the food additive, because
interactions with the food matrix may not occur;
• the effects observed on immunomodulation/inﬂammation were in line with those occurring in
the very early steps of the development of an inﬂammatory/immunological reaction. Variations
of different biomarkers were low (within 10–20% change), thus questioning the biological
relevance of the results, also taking into account the lack of historical data for that kind of
study;
• BSA coated on particles of TiO2 (E 171) could itself trigger an immunologic and/or allergic
reaction;
• although the model used to investigate the effects of TiO2 (E 171) in the development of
putative preneoplastic lesions in the colon was well described, the Panel noted some
limitations, such as the use of a single marker;
• the presence of ACF in the absence of an initiator is unusual, but in this study ACF were
observed in the colon of a few animals treated with TiO2 (E 171) alone;
• the initiation potential of TiO2 reported in this study was not observed in another study using
TiO2 (E 171) (Urrutia-Ortega et al., 2016);
• a publication by Wijnands et al. (2004), showed that the number and size of ACF induced by
different dietary compounds such as wheat bran, curcumin, rutin or benzyl isothiocyanate,
were not predictive for the ultimate number of colorectal tumours. Wijnands et al. (2004)
concluded that ‘the number and size of ACF were not considered to be suitable as biomarker
for colorectal cancer’, whereas the expression of some tumour-related genes (e.g.
metalloproteinase 1; TIMP-1) ‘correlated well with the effects of dietary compounds on the
ultimate tumour yield’.
Overall, based on the data provided in the Bettini et al. publication, and the negative results of the
carcinogenicity studies in mice and rats performed by NCI (1979), the Panel considered that the new
ﬁndings were not sufﬁcient to raise a concern on the potential initiation or promotion properties of
TiO2 (E 171) on colon carcinogenesis.
The Panel noted that determination of the presence of biomarkers for putative preneoplastic lesions in
the colon as additional parameters to be examined in the ongoing extended one-generation reproductive
toxicity study should be considered to substantiate the observations in the Bettini et al. (2017).
The Panel considered that there was not enough justiﬁcation at this stage for a new carcinogenicity
study as this would involve a large number of animals, but that, if additional mechanistic studies provided
useful information on the relevance of the reported results, this could be reconsidered in future.
9 http://ec.europa.eu/food/safety/food_improvement_agents/additives/re-evaluation_en
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Regarding the Proquin et al. (2017) study and the technical hearing in the Open ANS Plenary,1 the
Panel noted that:
• this in vitro study adds to a number of studies which provided some evidence of ROS
formation and in vitro genotoxicity by TiO2 MP and TiO2 NP in a variety of cell lines of human
and rodent origin (as reported in EFSA ANS Panel, 2016). These authors reported for the ﬁrst
time genotoxic activity in vitro in a Comet assay and cytokinesis-block micronucleus assay
using the food additive TiO2 (E 171). The Panel noted that, in view of the composition of TiO2
(E 171) (containing around 40% of nanoparticles by number), and of the available evidence of
genotoxicity in vitro of both TiO2 MP and TiO2 NP, a genotoxic activity of E 171 under in vitro
conditions could already be anticipated. In this respect, the Panel also noted that overall
negative results were obtained in studies in vivo with both TiO2 NP and MP (EFSA ANS Panel,
2016), indicating that TiO2 MP and NP, and consequently E 171, did not raise concern for
in vivo genotoxicity;
• two cell lines derived from human colon (adeno)carcinomas were selected as model system to
investigate the possible implication of ROS generation and genotoxicity in the promoting
activity of TiO2 (E 171) on chemically-induced colon carcinogenicity in mice reported in a
previous study (Urrutia-Ortega et al., 2016). Based on the discussion at the technical hearing
at the open Plenary, the Panel noted that this model appeared suitable for hazard
characterisation but not for the purpose of risk assessment;
• undifferentiated Caco-2 cells, harvested after only 3 days of culture, were used for the
assessment of DNA damage induced by TiO2. As to the relevance of the cell system used for
hazard characterisation, the Panel noted that another recent in vitro study highlighted a
comparable lower incorporation of TiO2 in differentiated compared to undifferentiated Caco-2
cells, and no induction of DNA damage in differentiated Caco-2 cells monolayers exposed to
TiO2 NP was observed (Vila et al., 2018). The Panel also noted that under in vivo conditions,
the uptake of TiO2 particles (including E 171) may be substantially decreased by the mucus
layer of the intestinal epithelium (Garcia-Rodriguez et al., 2018);
• concerning the claimed colocalisation of TiO2 (E 171) with ‘kinetochore poles, mitotic genome
and a-tubulin’, the Panel noted that no clear conclusion can be drawn from the ﬁgures
presented, which may be either indicative of a true colocalisation and functional interaction, or
arise from the unspeciﬁc overlap of TiO2 particles on cellular structures in the microscopic
preparation.
Overall, the Panel considered that the results reported in the Proquin et al. (2017) study may be
useful for an evaluation of the hazard of TiO2 nanoparticles under the speciﬁc conditions of the study
protocol, including the cell model used and the conditions of culture. However, the Panel also
considered that the relevance of the results for risk assessment of the food additive E 171 has not
been established.
During the discussion at the technical hearing at the open Plenary, one of the authors mentioned
that consistent results appeared to be observed in mouse colon in ongoing in vivo transcriptomics
studies. The Panel considered that these studies could be evaluated when completed, and if deemed
necessary, the overall database reassessed considering the entire literature available at that time.
The Panel concluded that the new in vitro ﬁndings provided in the study by Proquin et al. (2017)
do not modify the conclusion on the genotoxicity of TiO2 as stated in the previous EFSA opinion (2016)
on the safety of TiO2 (E 171) when used as a food additive.
Regarding the Guo et al. (2017) study and the technical hearing in the Open ANS Plenary,1 the
Panel noted that:
• the study was performed with engineered TiO2 NP and not with TiO2 as a food additive;
• the TiO2 NP suspension was sonicated to minimise agglomeration and/or aggregation which
may not occur in more realistic environments;
• in addition to the TEM analysis of primary particles, the DLS results suggested that the
hydrodynamic sizes were considerably larger which suggested that the TiO2 NP may be
aggregated and agglomerated;
• the authors assumed that all ingested particles would be in contact with the wall surface but
without considering the potential interaction of nanoparticles with luminal contents, e.g. their
estimated number of nanoparticles was comparable with the number of microorganisms per
gram of intestinal contents (ranges from 1056 in intestine to 1013 in colon);
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• the glycocalyx on cultured Caco-2 cells is different from that on normal human intestinal cells;
• the cells were rinsed in PBS before exposing them to TiO2 NP which could alter the glycocalyx
and the interactions of Caco-2 cells with TiO2 NP;
• changes in the expression of proinﬂammatory genes seen after 5-days of treatment with TiO2
NP were small, not dose-related and uneven;
• no information was available about possible markers of inﬂammation such as production/
secretion of cytokines, changes in the expression of membrane antigens;
• no transport of TiO2 NP across the Caco-2/Ht29 MTX monolayers was reported;
• as more physiological conditions were approached the effects were attenuated, and it was
difﬁcult to extrapolate these results to the in vivo situation;
Therefore, the Panel concluded that the results from the Guo et al. (2017) study cannot be
extrapolated to the human situation and cannot be used for the risk assessment of the food additive
TiO2 (E 171).
Regarding the Heringa et al. (2016) study and the technical hearing in the Open ANS Plenary,1 the
Panel noted that:
• the National Institute for Public Health and the Environment (RIVM) provided this and two
other unpublished reports at the time of the re-evaluation of the TiO2 (E 171) as a food
additive in 2016 (EFSA ANS Panel, 2016);
• these unpublished studies did not affect the Panel’s conclusions drawn from the available
database at that time;
• Heringa et al. assumed that, although there was no information available on the absorption of
TiO2 particles, any toxicity was caused by TiO2 NP;
• the conclusions of the authors that, because of uncertainties and assumptions in their analysis,
further studies would be needed, for example, on the actual concentration of nano-TiO2 in
human organs and on the effects in liver and the reproductive system after chronic exposure
to well-characterised TiO2 NP;
• data on reproductive toxicity were scarce;
• the results on effects on testosterone levels in the two studies (Jia et al., 2014; Tassinari et al.,
2014) used by Heringa et al. (2016) were contradictory;
• signiﬁcant uncertainties were associated with extrapolation from short term to lifetime
exposures;
• although the application of uncertainty factors for extrapolation from short term studies is a
policy choice, Heringa et al. used uncertainty factors from REACH rather than those
recommended by the EFSA SC (EFSA Scientiﬁc Committee, 2012);
• in deriving acceptable MoEi, the kinetic element of the inter- and intraspecies uncertainty
factors was only removed from the interspecies but not from the intraspecies uncertainty
factor;
• effects seen in short term studies with no functional effect in longer term studies are usually
not considered a robust basis for risk assessment.
Overall, the Panel considered that the aforementioned evaluations and considerations indicated that
there was signiﬁcant uncertainty in the assessment by Heringa et al. (2016) and noted that there was not
a weight of evidence analysis of the whole database on E 171. The Panel considered that the assessment
was consistent with a hazard from TiO2 NP when dosed as in the selected studies but the relevance to
nanoparticles in a food matrix could not be assessed. The Panel concluded that the additional studies
called for in its 2016 opinion should provide a more robust basis for addressing the reported effects in
reproductive organs in the studies used by Heringa et al. (2016).
4. Conclusions
Based on the evaluation of the four studies concerning the potential adverse health effects of
titanium dioxide, the Panel considered that:
• the results of the Bettini et al. (2017) study did not provide enough justiﬁcation for a new
carcinogenicity study, but, should additional useful mechanistic information become available,
this could be reconsidered in future;
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• the new in vitro ﬁndings in the study by Proquin et al. (2017) did not modify the conclusion on
the genotoxicity of TiO2 as stated in the previous EFSA opinion (EFSA ANS Panel, 2016) on the
safety of TiO2 (E 171) when used as a food additive;
• the effects of engineered TiO2 nanoparticles reported by the Guo et al. (2017) study were of
uncertain biological signiﬁcance and therefore of limited relevance for the risk assessment of
the food additive TiO2 (E 171);
• there was signiﬁcant uncertainty in the risk assessment performed by Heringa et al. (2016),
which did not include a weight of evidence analysis of the whole database;
• the four studies evaluated, highlighted some concerns but with uncertainties, therefore their
relevance for the risk assessment was considered limited and further research would be
needed to decrease the level of uncertainties.
Overall, three of the studies assessed in this opinion reported that TiO2 was able to induce various
effects in in vitro and in vivo models. These studies may be useful for hazard identiﬁcation of TiO2.
The Panel considered that the limited relevance of the protocols of these studies to the use of E 171
under realistic conditions in food hampered the use of the data in the risk assessment of the food
additive E 171. In the fourth study by Heringa et al. (2016), numerous assumptions were made, which
resulted in large uncertainty in their conclusion.
More research exploring the possible effects observed in three of the four studies could address
their applicability to the risk assessment of the food additive E 171 under realistic conditions of use.
Altogether, the Panel concluded that the outcome of the four studies did not merit re-opening the
existing opinion of EFSA related to the safety of TiO2 (E 171) as a food additive.
Recommendations
The Panel recommended that:
• in order to substantiate the observations in the Bettini et al. (2017), biomarkers for putative
preneoplastic lesions in the colon as additional parameters should be examined in the
extended one-generation reproductive toxicity study recommended by EFSA (EFSA ANS Panel,
2016);
• further studies on TiO2 NP should include administration in a food matrix.
Documentation provided to EFSA
1) Answers to questions shared with the authors of the four publications (attending as hearing
experts) to support the discussion at the ANS plenary meeting open to observers on 16 May
2018; submitted on 8 May 2018 by Prof Mahler (for the Guo et al., 2017; see Appendix D)
and on 15 May 2018 by Dr Houdeau (for the Bettini et al., 2017; see Appendix B) and Dr
Oomen (for the Heringa et al., 2016, see Appendix E).
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Abbreviations
ACF aberrant crypt foci
ADI acceptable daily intake
ANS Food Additive and Nutrient sources added to Food
ANSES French Food Safety Agency
BSA bovine serum albumin
DC dendritic cells
DLS dynamic light scattering
DMEM Dulbecco’s modiﬁed Eagle’s medium
DMH 1,2-dimethylhydrazine
ESR electron spin resonance
FBS fetal bovine serum
HBSS Hank’s balanced salt solution
IAP intestinal alkaline phosphatase
IFN-c interferon-c
IL interleukin
i.p. intraperitoneal
i.v. intravenous
LOAELs lowest observed adverse effect level
MoEe Margins of external Exposure
MoEi Margins of internal Exposure
MoS Margins of safety
MP microparticulate
NF-kb nuclear factor kappa B
NOAEL no observed adverse effects level
NP nanoparticles
PBS phosphate-buffered saline
PD Point of Departure
PP Peyer’s Patches
RIVM National Institute for Public Health and the Environment
ROS reactive oxygen species
SC Scientiﬁc Committee
SEM scanning electron microscopy
TiO2 titanium dioxide
TEM transmission electron microscopy
TNF-a tumour necrosis factor-a
WG Working Group
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Appendix A – ANSES Opinion 2017: English translation by the Panel of the
conclusions from the French original
On the basis of this study, ANSES concluded that the group of experts acknowledges the scientiﬁc
content of the publication and the data reported in spite of their limitations as discussed with the
authors. This study adds new information to the EFSA opinion (2016) as regards a potential promoting
effect of E 171.
The experts concluded that:
• the inﬂammatory effects reported in the in vivo studies appeared limited and their biological
signiﬁcance was not established. In addition, the statement about an inﬂammatory reaction
was not adequately substantiated by the data reported;
• as regards the Comet assay in the Peyer Patches, in the absence of positive controls in the
studies and of historical data, it is not possible to conclude on a possible genotoxic effect.
The data presented in this study do not question the risk assessment of E 171 performed by EFSA
and cannot be used before having been conﬁrmed by additional studies with E 171 administered to
animals in the food matrix. The potential promoting effect of E 171 in the colon must be conﬁrmed by
longer term studies, which should evaluate more biomarkers. In these studies, an additional treated
group with a sufﬁcient number of animals is needed before being able to conclude on a possible
initiating effect of E 171.
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Appendix B – Questions and answers to the authors of the Bettini et al. (2017)
study
1) On page 9 under ‘Animals and experiments design’, the three series of experiments are
described. The Panel would like to know whether the rats were fasted in the ﬁrst series of
toxicological studies before treating them by gavage.
Answer: No, rats were not fasted before oral treatment with TiO2, and whatever the study
(one week through gastric gavage or 100 days in drinking water).
2) Could you please tell us if the potential agglomeration of ultrasonicated test material was
check before its administration to the animals?
Answer: Yes, the dispersion state was checked by DLS before treatment to rats (no change
upon 48 h). Ultrasonicated TiO2 suspension orally given to rats in water was thus renewed
every 2 days to ensure stable dispersion state during experiments.
3) On page 2 under ‘Results’, it is mentioned that titanium dioxide particles were found in the
Peyer’s Patches (PP) of the small intestine, colonic mucosa and liver of rats administered
TiO2 (E 171) by gavage for 7 days, but not in the controls. In the same rats, Ti was
detected in the gut lumen, PP, colon mucosa and liver. In this respect:
• The Panel is aware that in other publications, background levels of Ti have been reported
in control animals in experimental studies on Ti absorption from nanoparticles. What is
your explanation of the fact that in your study, no Ti was detected in control rats?
Answer: TiO2 is rapidly absorbed: ≤ 6–8 h after a single dose, and does not accumulate
signiﬁcantly into the intestinal wall (unpublished); repeated exposure is needed (e.g. daily
for one week or more) to observe particles into the gut mucosa and cells; our studies were
performed with nano-SIMS and lXRF imaging, after application of a threshold to extract
the Ti signal over the background noise: no Ti level measurements were performed in this
study (e.g. ICP-MS).
• How much Ti was detected in the liver?
Answer: Not measured, but all organs were available for ICP-MS dosage (100-day study).
• Could it be a difference in absorption and distribution between a bolus administration and
a chronic exposure in drinking water?
Answer: No difference observed between bolus and drinking water.
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Appendix C – Questions and answers to the authors of the Proquin et al.
(2017) study
1) On page 140 and 141 under ‘Materials and methods’, it is described that the Caco-2 cell
lines (at passage 24–32) ‘were cultured for three days to reach 80–100% conﬂuency before
exposing them to different concentrations of E 171, TiO2 MP, or TiO2 NP’. The Panel noted
that, according to the literature, the differentiation of Caco-2 cells may require as much as
three weeks in culture before being fully achieved. In this respect:
• Could you please clarify the rationale for choosing a shorter period in culture (3 days)
before the treatment with the test materials?
• Would you consider that these experimental conditions could have affected the
representativeness of this cell model to extrapolate to an in vivo situation?
2) The Panel considered your ﬁndings on ROS generation. On page 144 (ﬁgure 4), under cell-free
conditions, only TiO2 NP (at mid-dose) and E 171 (at the highest dose) induced a signiﬁcant
increase in ROS generation compared to the control. Conversely, it is stated that in Caco-2
cells only TiO2 MP (at the mid concentration) produced a signiﬁcant increase of ROS compared
to the control. However, data in ﬁgure 5 (page 145), show higher signals of cellular radical
formation for controls than MP-treated cells. Could you please explain how data on ROS
formation in Caco-2 cells are interpreted to reach such conclusion? Moreover, how do you
interpret the inconsistency in the ﬁndings on the ROS generation in cell-free and cellular
conditions, and how do you consider this in reaching the ﬁnal conclusion on this endpoint?
3) In ﬁgure 6 on page 145, showing the results of the Comet assay, you stated that the DNA
damage in Caco-2 cells was dependent on the size of the particles. Could you please explain
this statement in relation to the results presented in ﬁgure 6?
Witten answers to these questions were not provided, but these were answered during the
discussion at the technical hearing at the ANS Plenary open to observers1.
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Appendix D – Questions and answers to the authors of the Guo et al.
(2017) study
1) It is noted that the daily intake of titanium dioxide nanoparticles has been reported to be
1012–1014 nanoparticles per day. In this respect, could you please provide more information
on how these doses were converted to nanoparticles per meal, and particle per mL?
Answer: The doses used in this study were based on the published TiO2 consumption
estimates made by Lomer et al. (2004). We took these estimates (in mass), converted them
to a number of 30 nm nanoparticles, and divided that number of nanoparticles by the
surface area of the small intestine. This density of exposure was then matched in an in vitro
model.
2) Under 2.6 ‘Acute and chronic exposure to NPs’, it is noted that the ‘NP solutions were made
fresh every day’. Could you please explain whether doses expressed as particle/ml were also
daily measured?
Answer: The chronic exposure solutions were made fresh daily. This was because when we
measured these solutions after they had been stored for 24+ h there was a great deal of
particle aggregation. The measurements on nanoparticle characteristics were performed on
solutions that were made freshly using the same methods as we used to make our exposure
solutions. The zeta potential, etc. was not measured before every exposure experiment.
3) Under 2.1 ‘Nanoparticles dose calculations’ the following it is stated: ‘Chronic doses were
three times (3X) the acute dose’. Could you please clarify the regimen of the administration
of the doses for the chronic exposure (e.g. one single dose, repeated doses, etc.)?
Answer: For the chronic exposure experiments, the medium containing a known amount of
nanoparticles was replaced every 24 h for ﬁve days.
4) The Panel noted that the cell surface structure (e.g. glycocalyx amount and composition,
which is of importance in regulating the possible interactions of cells with particles), is
dependent on the culture conditions. In this study, the cells were cultured for 16 days
instead of 21 as usually done (Frey et al., 1996; Ramaker et al., 2016). It is however
acknowledged that co-culture with HT29-MTX cells favour the constitution/composition of
glycocalyx. No TEM analysis of the cell cultures was performed (only scanning) and there
was no direct observation of the glycocalyx. In addition, the cells were rinsed in PBS before
exposing them to titanium dioxide nanoparticles. In this respect, could you please discuss
what could be the consequence of an altered glycocalyx on the interactions of Caco 2 cells
with titanium dioxide nanoparticles?
Answer: We have been developing assays that assess the mucus layer following exposure to
various food additives. We do not yet have reliable data.
5) Could you please clarify why cell cultures treated with TiO2 but not exposed to Fe or Zn
isotopes were not used when looking at ROS generation and gene expression?
Answer: Cells exposed to Fe and Zn were used for gene expression studies.
6) In this study, no cytotoxicity tests were performed on the Caco 2 cells treated with TiO2; the
doses applied were considered to be non-cytotoxic based on data from the literature.
However, culture conditions (time, number of passages, co-culture,) are known to inﬂuence
cell morphology/physiology, which, as a result may modify the response of cells to a
cytotoxic compound. In addition, in this study, it is reported a marked decrease in the Trans
Epithelial Resistance (TER) in the cells that had received chronic doses of TiO2, but not an
acute dose. Could you please discuss the consequence of these observations as regards
interaction of TiO2 with the cell surface and the resulting reported effects? Alkaline
phosphatase activity is expressed per mg of cell protein. What were the changes in the cell
protein content between treated and untreated cultures?
Answer: We have done more studies on TiO2 effects on gut permeability with an in vivo
(drosophila) model. Based on that data (currently under review) I do not think that TiO2 has
a signiﬁcant effect on gut permeability. I can look at the cell protein raw data to see if there
were dramatic changes in cell protein content. I do not believe that there were, and I
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cannot conﬁdently say that changes in cell protein are the result of TiO2 exposure or
inefﬁciencies in the sonication method we used to disrupt the cell membrane. As we have
continued to perform this assay we have found that to fully release cell protein into solution
we need to scrape the well and then sonicate the solution a second time.
7) The study reported some variations in the expression of proinﬂammatory genes after
treatment with ‘chronic doses’ of TiO2 only, not after exposure to ‘acute doses’. These
variations were limited, not dose-related, variable; e.g. for TNF-, there was a signiﬁcant
increase for Zn (at one dose), and a signiﬁcant decrease (at two doses) for Fe. As regards
NFKB1, there was a signiﬁcant decrease at one dose for Fe and a signiﬁcant increase at the
same dose for Zn. Could you please discuss the biological signiﬁcance of these changes? Do
you have any information about other modiﬁcations of Caco 2 cells that might be associated
with these variations in the expression of proinﬂammatory genes; e.g. production/secretion
of cytokines, changes in the expression of membrane antigens, etc.?
Answer: No, we did not measure the secretion of additional cytokines.
8) Could you please provide your opinion on how this in vitro model is representative of an
in vivo situation in human?
9) Why do you assume that exposure to particles is occurring at the wall of the gastrointestinal
tract rather than with the contents in the lumen and ignore that in vivo exposure is more
likely to result in interactions with the luminal contents (food, digestive enzymes, chime,
microﬂora). Theses interactions are likely to modify the nanoparticulate material so how
relevant is their administration in a medium intended to maintain them as nanoparticles on
the cell surface to the in vivo situation?
Answer to Questions 8 and 9: This study was the ﬁrst that our lab published on nano-TiO2
exposure. We have since made efforts to make the in vitro model more realistic by including
bacteria (https://doi.org/10.1080/17435390.2018.1457189) and studying the food additives
in a food matrix (under review). Based on those results I would say that a more
complicated model, or in vivo studies, may be needed to fully assess the effects of TiO2
nanoparticles on gut function, although a simpliﬁed cell culture model may be useful for
deciding on which materials to test or directing resources toward more complex studies.
When we added a beneﬁcial bacteria to our cell culture model, for example, the effects of
TiO2 nanoparticle exposure were remediated. We have also performed studies in vivo to
look at the functional effects of TiO2 ingestion and changes to the microbiota, but that data
has not been peer reviewed or published yet.
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Appendix E – Questions and answers to the authors of the Heringa et al.
(2016) study
1) It was noted that from the NCI (1979) study, you identiﬁed a LOAEL based on the non-
neoplastic effects observed (e.g. hyperplasia of bile ducts), whereas in the EFSA Scientiﬁc
Opinion a NOAEL was identiﬁed from this same study based on the absence of
carcinogenicity. Could you please explain the rationale behind this choice?
Answer: The NCI (1979) study was a study focused on potential carcinogenicity and reports
a NOAEL at the highest tested dose of 50,000 ppm (corresponding to 2,500 mg/kg bw per
day in rat). In this study, no signiﬁcant increase in tumours was found. However, in the non-
neoplastic analyses in this study, as given in the study annexes, a number of effects were
reported.
In Appendix C, on non-neoplastic lesions in the rat, Table C1 (for male rats) shows the following
incidences with a clear dose–response relationship or a clear effect of TiO2 dosage (in italics):
Lesion
Incidence in
control group
(n = 49)
Incidence in low-dose
group (1,250 mg/kg bw
per day in rat) (n = 50)
Incidence in high-dose
group (2,500 mg/kg bw
per day in rat) (n = 50)
Lung: Congestion 0 6 (12%) 13 (27%)
Lung: haemorrhage 0 5 (10%) 6 (12%)
Heart: ﬁbrosis 1 (2%) 8 (16%) 12 (24%)
Liver: bile duct
hyperplasia
0 21 (42%) 27 (54%)
Seminal vesicle:
atrophy
0 6 (12%) 10 (20%)
Table C2 (for female rats) shows the following incidences with a clear effect of TiO2 dosage (in italics):
Lesion
Incidence in
control group
(n = 50)
Incidence in low-dose
group (1,250 mg/kg bw
per day in rat) (n = 50)
Incidence in high-dose
group (2,500 mg/kg bw
per day in rat) (n = 49)
Lung: Congestion 0 12 (24%) 10 (20%)
Lung: haemorrhage 1 (2%) 8 (16%) 9 (18%)
Heart: ﬁbrosis 0 10 (20%) 5 (10%)
Liver: bile duct
hyperplasia
0 14 (28%) 14 (29%)
Mammary gland:
galactocele
2 (4%) 14 (28%) 14 (29%)
In Appendix D, on non-neoplastic lesions in the mouse, Table D1 (for male mice) shows the following
incidences with a clear dose–response relationship or a clear effect of TiO2 dosage (in italics):
Lesion
Incidence in
control group
(n = 50)
Incidence in low-dose
group (1,250 mg/kg bw
per day in rat) (n = 50)
Incidence in high-dose
group (2,500 mg/kg bw
per day in rat) (n = 49)
Mesenteric lymph
node:
lymphangiectasis
1 (2%) 12 (25%) 15 (31%)
Liver: necrosis 0 0 8 (16%)
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Table C2 (for female mice) shows the following incidences with a clear effect of TiO2 dosage
(in italics):
Lesion
Incidence in
control group
(n = 49)
Incidence in low-dose
group (1,250 mg/kg bw
per day in rat) (n = 50)
Incidence in high-dose
group (2,500 mg/kg bw
per day in rat) (n = 50)
Uterus: hyperplasia,
cystic
17 (35%) 42 (86%) 38 (78%)
Ovary: follicular cyst 1 (2%) 11 (23%) 8 (17%)
We have asked for historic control values for these rats at this institute, but these were not
available according to the institute. Thus, perhaps the increased incidences in the exposed groups lie
within the historic control range and were therefore not seen as signiﬁcant by the study directors.
However, we considered that the chance of seeing a > 10% increase in incidence (i.e. > 5 additional
animals showing the effect, of the 50 animals in the group) precisely in the exposed groups only, and
this being due just to background variation, should be quite small, even if such incidences had been
found sometimes in the past in a control group. We can thus not fully exclude that the increases are a
natural variation in these cases, but it is more likely that the increase in incidence is then caused by
the exposure. In addition, we see a large correspondence between the male and female rats in these
increased incidences, making it even more likely that the effects seen in rats are not caused by natural
variation, but by the exposure. The fact that the higher dose often does not give a much higher
response than the lower dose, may be explained by a potential limit in the absorption capacity in the
gut at these very high doses. Finally, some of the organs affected correspond to organs where other
key studies, with TiO2 nanoparticles speciﬁcally, have reported effects as well: liver (Wang et al., 2013)
and ovary (Tassinari et al., 2014). Seminal vesicles were not analysed by Jia et al. (2014) or others as
far as we are aware, while Jia et al. (2014) did report other effects on the male reproductive organs.
The mammary gland has not been analysed by any oral TiO2 study either, as far as we know, the
uterus only in a 5-day study, in which hyperplasia can hardly form.
Altogether, we found that these effects cannot be dismissed, but should be taken along in our risk
assessment, together with other study results. We therefore suggest that a LOAEL may be set at the
lowest tested dose: 25,000 ppm (or 1250 mg/kg bw d in rats).
2) Could you please provide your opinion whether the results from the dietary Extended
One-Generation Reproductive Toxicity study, which was commissioned by the industry
following a request from the European Commission in response to the
Panel recommendations further to the re-evaluation of titanium dioxide (E 171) as a food
additive, would be sufﬁcient to address the effects discussed in your publication? If not,
what additional study would you recommend?
Answer: According to the website of the European Commission, the dietary Extended
One-Generation Reproductive Toxicity study would include developmental neurotoxicity,
developmental immunotoxicity and various endocrine parameters. It was recommended in
Heringa et al. (2016) to obtain more clarity on endocrine effects and effects on fertility,
which should be addressed in the study requested by the EC.
Furthermore, it is indicated that tissue and urine levels of titanium will be monitored. As we
consider it is important that the risk assessment of TiO2 should be based on internal
concentrations, we highly appreciate that tissue levels of titanium will be determined.
However, it is unclear which tissues will be analysed and at which time points. In line with the
EFSA draft guidance, in particular information on the absorption/bioavailability, distribution
pattern and clearance is considered relevant. To that end, tissues should be analysed after
multiple time points. Also the addition of a satellite group to investigate the elimination of Ti is
recommended. The tissues that are considered most relevant to analyse are, to our opinion:
liver, spleen, lymph nodes, git tissue, gonads and possibly brain and bone marrow.
Also in line with the EFSA draft guidance, analysis of the presence of TiO2 particles (rather
than the element Ti) and their size in these tissues would be encouraged, although this may
be technically challenging. Our recent study (Heringa et al., 2018) suggests that all Ti found in
tissues was present as TiO2 particles.
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We also highly recommend investigating markers of liver damage (e.g. ALT, AST, ALP, bilirubin)
and liver (including bile duct) pathology. This can be performed in the animals in the
Reproductive study or in separate subchronic or chronic oral toxicity study. Based on other
studies (Bettini et al., 2017), assessment of effects on the intestine should also be considered.
Furthermore, we recommend applying the benchmark dose approach, using more dose
groups with smaller numbers of animals (hence, using the same total number of animals). In
this way, it is possible to get a good dose–response curve, which can also be expressed based
on internal tissue concentration levels. High doses of particles may lead to agglomeration of
the particles which may affect the absorption. Due to this phenomenon, the fraction
absorption may be smaller than at lower (more realistic) concentrations. The inclusion of lower
dose groups that are more representative for human exposure should therefore be considered
in addition to higher dose groups.
Finally, it should be noted that TiO2 in E 171 can be present in different ‘forms’ due to
differences in crystal structure (anatase, rutile or a mixture), uncoated or coated with e.g.
silica or alumina, or with different size distributions. It is known that such differences can
affect toxicokinetic behaviour and hazard and thereby risk, but at present there is no
understanding of how these physicochemical differences affect toxicokinetics and hazard and
neither on which TiO2 form would be worst case in terms of risk. Hence, it is considered
relevant to test multiple forms and to develop a scientiﬁcally substantiated read-across
argument to cover all forms of TiO2 applied in food.
In summary, we are of the opinion that the study will provide valuable information.
Nevertheless, we have a number of recommendations that we think are important to include:
• Perform the tissue monitoring in such a way that information on the absorption/
bioavailability, distribution pattern and clearance is obtained.
• Investigate markers of liver damage (e.g. ALT, AST, ALP, bilirubin) and liver (including bile
duct) pathology. Also consider effects on the intestine.
• Apply a benchmark dose approach to get a good dose–response curve which includes
both lower dose groups that are more representative for human exposure as well as
higher dose groups.
Consider that TiO2 in E 171 can be present in different ‘forms’ and that the risk assessment of
E 171 should cover all.
3) It was noted that in your risk assessment, the oral intake of titanium dioxide calculated by
Rompelberg et al. (2016) was considered. In that publication, the oral intake of titanium
dioxide was calculated from the exposure to food, food supplements and toothpaste. Could
you please explain how the use of toothpaste could contribute to the oral intake of titanium
dioxide from dietary sources?
Answer: We considered the oral intake of TiO2 rather than the intake from dietary sources.
As toothpaste is ingested to some extent by small children, this was taken into
consideration. In Rompelberg et al. (2016) it was therefore assumed that children aged 2–6
years all toothpaste applied on a brush is swallowed. Swallowing the toothpaste for this age
group is also advised to achieve a sufﬁcient daily ﬂuoride intake to prevent caries. The
self-estimated portion of toothpaste per brushing event was 1.15  0.14 g. When
considering lifelong exposure, the contribution of toothpaste is limited.
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